Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Assets: 2015-2024

Historic Assets for Spyre Therapeutics (SYRE) over the last 10 years, with Dec 2024 value amounting to $608.5 million.

  • Spyre Therapeutics' Assets rose 19.83% to $504.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $504.6 million, marking a year-over-year increase of 19.83%. This contributed to the annual value of $608.5 million for FY2024, which is 77.99% up from last year.
  • According to the latest figures from FY2024, Spyre Therapeutics' Assets is $608.5 million, which was up 77.99% from $341.9 million recorded in FY2023.
  • Over the past 5 years, Spyre Therapeutics' Assets peaked at $608.5 million during FY2024, and registered a low of $71.1 million during FY2022.
  • For the 3-year period, Spyre Therapeutics' Assets averaged around $340.5 million, with its median value being $341.9 million (2023).
  • As far as peak fluctuations go, Spyre Therapeutics' Assets tumbled by 35.28% in 2022, and later spiked by 380.52% in 2023.
  • Yearly analysis of 5 years shows Spyre Therapeutics' Assets stood at $161.6 million in 2020, then slumped by 31.98% to $109.9 million in 2021, then slumped by 35.28% to $71.1 million in 2022, then soared by 380.52% to $341.9 million in 2023, then skyrocketed by 77.99% to $608.5 million in 2024.